Philippe Douville
CEO
Find therapeutics
Find Therapeutics designs modulators targeting membrane receptors to develop therapies for autoimmune diseases. The company focuses on drug discovery and development to provide effective treatment options for patients suffering from these conditions.
- Biotechnology
Updated 11 months ago
Funding
Raised to date
$8.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
ABCLIQ
$8.1M · Series A
Announced Sep 2024
Disclosed cumulative: $8.1M
RoundDateAmountValuationInvestors
Founders
Product
Problem
Current treatment options for autoimmune diseases often fail to address the underlying causes and can have significant side effects. There remains a need for more targeted and effective therapies that can modulate the immune response without causing broad immunosuppression.
Solution
Find Therapeutics is developing a new class of therapeutics that precisely target membrane receptors to treat autoimmune diseases. The company utilizes innovative chemistry to design modulators that can fine-tune the activity of key receptors involved in immune signaling pathways. By selectively modulating these receptors, Find Therapeutics aims to restore immune balance and resolve the underlying causes of autoimmune disorders. Their lead candidate, FTX-101, is currently in Phase 1 clinical trials.
Target Audience
The primary target audience includes patients suffering from various autoimmune diseases, as well as pharmaceutical companies seeking novel therapeutic candidates in the immunology space.
Features
- Focus on precision-targeting of membrane receptors relevant to autoimmune disease pathways.
- Development of novel small-molecule modulators with improved selectivity and efficacy.
- FTX-101: Lead drug candidate currently in Phase 1 clinical trials.
- Innovative chemistry platform for rational drug design and optimization.